Allianz SE Sells 909 Shares of Eli Lilly and Company $LLY

Allianz SE reduced its stake in shares of Eli Lilly and Company (NYSE:LLY) by 2.2% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 39,590 shares of the company’s stock after selling 909 shares during the period. Eli Lilly and Company accounts for 0.6% of Allianz SE’s portfolio, making the stock its 27th biggest holding. Allianz SE’s holdings in Eli Lilly and Company were worth $30,207,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently modified their holdings of LLY. Vanguard Group Inc. grew its position in shares of Eli Lilly and Company by 0.7% during the third quarter. Vanguard Group Inc. now owns 80,959,089 shares of the company’s stock worth $61,771,785,000 after purchasing an additional 551,659 shares in the last quarter. Laurel Wealth Advisors LLC lifted its stake in Eli Lilly and Company by 78,621.2% in the 2nd quarter. Laurel Wealth Advisors LLC now owns 11,552,336 shares of the company’s stock worth $9,005,392,000 after purchasing an additional 11,537,661 shares in the last quarter. Norges Bank bought a new position in shares of Eli Lilly and Company during the 2nd quarter valued at about $8,827,714,000. Charles Schwab Investment Management Inc. boosted its holdings in shares of Eli Lilly and Company by 2.0% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 5,359,653 shares of the company’s stock valued at $4,178,010,000 after purchasing an additional 103,119 shares during the last quarter. Finally, Franklin Resources Inc. grew its position in shares of Eli Lilly and Company by 13.4% during the second quarter. Franklin Resources Inc. now owns 4,766,865 shares of the company’s stock valued at $3,715,913,000 after purchasing an additional 564,736 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Topline ACHIEVE‑3 results for type 2 diabetes showed meaningful A1C and weight benefits for Lilly’s oral GLP‑1 in a head‑to‑head setting, reinforcing the drug’s commercial and regulatory potential. Lilly reports ACHIEVE-3 trial outcomes for type 2 diabetes
• Positive Sentiment: Detailed Phase 3/Lancet results show orforglipron outperformed oral semaglutide on A1C and weight in ACHIEVE‑3, strengthening Lilly’s case for market share and supporting upcoming regulatory timelines (U.S. obesity decision possible in Q2). Orforglipron Lancet results PR Newswire
• Positive Sentiment: CHMP issued a positive opinion for expanded EU use of Olumiant (baricitinib) in adolescents with severe alopecia areata — a near‑term regulatory win that expands labeled indications and revenue opportunities in Europe. Olumiant CHMP positive opinion PR Newswire
• Positive Sentiment: RBC Capital initiated coverage with an Outperform and $1,250 PT, signaling institutional confidence in Lilly’s obesity leadership; coupled with recent price‑target increases from other shops, this boosts investor conviction. RBC Capital initiates Eli Lilly
• Positive Sentiment: High‑profile media/TV endorsements (e.g., Jim Cramer recommending Lilly over Novo Nordisk) are supportive for retail flows and sentiment toward LLY. Jim Cramer Recommends Eli Lilly
• Neutral Sentiment: Reuters published additional trial safety data giving a more detailed picture of side effects — useful context for regulators and investors but not a clear negative or positive on balance. Reuters: additional data on weight-loss pill
• Neutral Sentiment: Health‑care stocks broadly moved higher today, which can amplify sector leaders’ moves but may reflect macro/flow dynamics rather than company‑specific fundamentals. Sector Update: Health Care Stocks Higher
• Negative Sentiment: Smaller rivals (e.g., Viking Therapeutics) and other entrants remain active in the obesity space — a potential long‑term competitive risk that could pressure pricing and market share over time. Viking Therapeutics profile

Eli Lilly and Company Trading Up 2.8%

NYSE LLY opened at $1,050.39 on Friday. The firm has a market cap of $990.90 billion, a PE ratio of 45.77, a price-to-earnings-growth ratio of 1.19 and a beta of 0.39. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,133.95. The company has a quick ratio of 1.19, a current ratio of 1.58 and a debt-to-equity ratio of 1.54. The company has a 50 day moving average price of $1,053.15 and a 200 day moving average price of $928.02.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share (EPS) for the quarter, topping the consensus estimate of $7.48 by $0.06. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. The business had revenue of $19.29 billion for the quarter, compared to analyst estimates of $17.85 billion. During the same period in the previous year, the company earned $5.32 earnings per share. The business’s revenue for the quarter was up 42.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. As a group, sell-side analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 13th will be given a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, February 13th. This represents a $6.92 annualized dividend and a yield of 0.7%. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. Eli Lilly and Company’s payout ratio is presently 30.15%.

Analysts Set New Price Targets

A number of research analysts have recently commented on LLY shares. Bank of America lowered their target price on Eli Lilly and Company from $1,286.00 to $1,268.00 and set a “buy” rating for the company in a research report on Monday, December 15th. TD Cowen boosted their price objective on shares of Eli Lilly and Company from $960.00 to $1,250.00 and gave the company a “buy” rating in a research report on Thursday, January 29th. Daiwa Securities Group raised their target price on shares of Eli Lilly and Company from $1,230.00 to $1,250.00 and gave the stock a “buy” rating in a report on Wednesday, February 18th. Wall Street Zen downgraded shares of Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a report on Saturday, January 31st. Finally, Wells Fargo & Company raised their price target on Eli Lilly and Company from $1,200.00 to $1,280.00 and gave the stock an “overweight” rating in a research note on Thursday, February 5th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $1,229.59.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.